The Real Economy Blog

vaccine

5 things to know in life sciences: Week of March 22

by , and

In this week’s life sciences roundup: the AstraZeneca-Oxford COVID-19 vaccine has faced challenging headwinds in the past week as several European Union countries paused distribution pending additional information from the European Medicines Agency, and as the National Institute of Allergy and Infectious Diseases in the United States publicly rebuked data ... READ MORE >

5 things to know in life sciences: Week of Feb. 1

by and

In this week’s roundup, we examine why more drug manufacturers are not stepping in to help produce mRNA-based COVID-19 vaccines. While some may think drug manufacturing facilities should be able to easily pivot to produce these vaccines, the reality is much more complicated. We also look at investment patterns in gene therapy companies, a new Food and ... READ MORE >

5 things to know in life sciences: Week of Jan. 18

by and

Now that President Joe Biden has taken office, there will soon be a host of new faces in positions with significant influence over the life sciences industry, as the first item in our roundup this week explains. These include new leaders at the Centers for Disease Control and Prevention and the Department of Health and Human Services, key roles in the ... READ MORE >

5 things to know this week in life sciences: Week of Jan. 4

by and

Each year, pharma companies make updates to their price lists in January. This reliably generates headlines and, occasionally, congressional hearings. In this week’s industry roundup, we take a look at the recent price increases and how they compare to last year’s. We also look at the ongoing battle over 340B program discounts between pharma companies and ... READ MORE >

5 things to know this week in life sciences: Week of Dec. 21

by and

With approval of Moderna’s COVID-19 vaccine last week for emergency use, many of us are looking forward to getting vaccinated with the hope that it will help us return to a more normal life. While looking forward, this is also a good time to reflect on the decades of work that laid the groundwork for this lightning fast vaccine development effort, as the ... READ MORE >

CHART OF THE DAY: Vaccine doses for the global population

by

With the U.S. Food and Drug Administration set to review Pfizer and BioNTech’s COVID-19 vaccine this week for emergency use authorization and Moderna’s vaccine next week, we have passed the “if” phase of questions around the vaccine. Now, the focus turns to the “when and how” of distribution. The United States expects to have enough COVID-19 vaccines ... READ MORE >

Looking ahead: next steps for the economy after Pfizer’s promising vaccine news

by , and

Pfizer and German biotech firm BioNTech’s Monday announcement that their COVID-19 vaccine candidate has shown to be more than 90% effective in preliminary results from an ongoing trial is a much needed win in the fight against the pandemic. It carries significant economic implications regarding the potential unlocking of close to $4 trillion in impaired ... READ MORE >

CHART OF THE DAY: The race to find a coronavirus vaccine

by

Scientists have been working at a blistering pace to shorten the vaccine development cycle from years to months in order to take a coronavirus vaccine to market. With more than 190 such vaccines in development, there are several leading the pack. Two trials, by AstraZeneca and Johnson & Johnson, had been halted because participants had become sick. ... READ MORE >

The search for a safe and effective coronavirus vaccine

by and

Regardless of race, religion or socioeconomic status, one thing most, if not all, Americans can agree on is that we are tired of the pandemic and the economic, health and political fallout we have collectively experienced from it. And while there may be disagreement about the best way to approach the pandemic, it is generally held that a safe, effective ... READ MORE >